Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Big Japanese Pharmas Unlikely To Replace Expiring Patents With M&As

This article was originally published in PharmAsia News

Executive Summary

Analysts believe the mergers-and-acquisitions drive of Japan's large drug makers is not likely to fill the void the companies face as their best-selling brands lose patent protection. Several Japanese pharmas have acquired foreign firms to help refill their dwindling portfolios, but analysts say that move is not likely to be enough to keep the companies from falling off what one said was a patent cliff. Drug makers in other countries have faced similar problems over the past 10 years, but this is the first time Japanese pharmas have faced the cliff. So far, Daiichi Sankyo is the only large maker that has not faced the loss of patent protection for a major drug. (Click here for more

You may also be interested in...

EU Business Round-Up: Sanofi Pens Enzymatica Deal, Germany's WindStar Acquired, Ipsen's Sales Slump

Latest EU company news: Sanofi grows OTC portfolio in France and Italy with ColdZyme; Germany's WindStar Medical gets UK owners; and France's Ipsen continues to fell effects of COVID-19 on sales.

Coronavirus Update: Lilly’s Antibody Plus Remdesivir Trial Abandoned

Combination of antibody therapy and Gilead's Veklury fails to show potential in patients with advanced disease.

Generic Drug Approvals Drop For The First Time In Five Years

The FDA’s generic drug program yearly performance report shows that generic drug approvals declined for the first time in five years in fiscal year 2020, and the agency also reported a lower number of ANDA submissions.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts